Glenmark Pharmaceuticals Ltd

The approval resulted from a collaboration between Glenmark and Cosmo Pharmaceuticals N.V. The approval covers the treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with usage in adolescents restricted to facial application. Glenmark will commercialize the product across 15 European countries: Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, and Sweden. Christoph Stoller, President & Business Head ' Europe and Emerging Markets of Glenmark Pharmaceuticals, said, 'The approval is a key milestone in executing our mission to become a research-led, global pharmaceutical company. Winlevi is the first NCE launch of Glenmark in Europe and is key to strengthening our presence in dermatology in the region. We are committed to executing successful launches with urgency and precision, ensuring timely access for patients in full alignment with regulatory and access frameworks.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25. Shares of Glenmark Pharmaceuticals fell 1.12% to Rs 1,844.65 on the BSE.Powered by Capital Market - Live

Cosmo Pharmaceuticals N.V. and Glenmark Pharmaceuticals announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi' (clascoterone 10 mg/g cream), following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on 25 August 2025. Winlevi' is authorized in EU for the treatment of acne vulgaris in both adults and adolescents aged 12 to 18 years, with usage in adolescents limited to facial application. With receipt of this approval, Glenmark will initiate commercializing Winlevi' across 15 countries in EU namely Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain and Sweden. Powered by Capital Market - Live

Profit before tax (PBT) surged 104.7% YoY to Rs 967.40 crore in Q2 FY26. EBITDA was Rs 2,359.6 crore in the quarter ended September 30, 2025, as compared to Rs 601.9 crore in the corresponding quarter of the previous year, registering growth of 292% and an EBITDA margin of 39%. In India, sales from the formulation business in Q2 FY26 were at Rs 165 crore as against Rs 1,281.7 crore posted in the previous corresponding quarter, recording a decline of 87.1% The North America business recorded sales of Rs 4,465.6 crore for the second quarter of FY26 as against revenue of Rs 740.5 crore for the second quarter of FY25. Glenmark Europe's operations revenue for the second quarter of FY26 was Rs 746.0 crore as against Rs 687.4 crore and recorded a growth of 8.5% YoY. The company continues to focus on sustaining the increasing contribution from the branded markets / portfolio in Europe. For the second quarter of FY 2026, revenue from emerging markets was Rs 658.5 crore as against Rs 704.1 crore for the previous corresponding quarter, recording a decline of 6.5% YoY. Glenn Saldanha, chairman & managing director, Glenmark Pharmaceuticals, said, 'Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the pipeline in a financially self-sustaining way. Across key markets, our performance remained resilient. North America delivered a continued uptick in performance, supported by the expansion of our injectable portfolio and steady execution across institutional channels. Europe returned to its growth trajectory, backed by recent product launches. In India, GST-related adjustments, given our unique three-tiered distribution model, had a one-time impact on primary sales; however secondary sales continue to outperform IPM, and we expect reported growth to normalize from Q3 onwards. Our specialty and innovation businesses progressed several important milestones this quarter including the global expansion of Ryaltris, the UK launch of Winlevi, the regulatory and clinical milestones achieved for QiNHAYOTM, and our IGI oncology assets. We remain committed to disciplined execution, advancing meaningful science, and delivering sustained value for our patients, partners, and all stakeholders.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets.Powered by Capital Market - Live

Profit before tax (PBT) surged 104.7% YoY to Rs 967.40 crore in Q2 FY26. EBITDA was Rs 2,359.6 crore in the quarter ended September 30, 2025, as compared to Rs 601.9 crore in the corresponding quarter of the previous year, registering growth of 292% and an EBITDA margin of 39%. In India, sales from the formulation business in Q2 FY26 were at Rs 165 crore as against Rs 1,281.7 crore posted in the previous corresponding quarter, recording a decline of 87.1% The North America business recorded sales of Rs 4,465.6 crore for the second quarter of FY26 as against revenue of Rs 740.5 crore for the second quarter of FY25. Glenmark Europe's operations revenue for the second quarter of FY26 was Rs 746.0 crore as against Rs 687.4 crore and recorded a growth of 8.5% YoY. The company continues to focus on sustaining the increasing contribution from the branded markets / portfolio in Europe. For the second quarter of FY 2026, revenue from emerging markets was Rs 658.5 crore as against Rs 704.1 crore for the previous corresponding quarter, recording a decline of 6.5% YoY. Glenn Saldanha, chairman & managing director, Glenmark Pharmaceuticals, said, 'Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the pipeline in a financially self-sustaining way. Across key markets, our performance remained resilient. North America delivered a continued uptick in performance, supported by the expansion of our injectable portfolio and steady execution across institutional channels. Europe returned to its growth trajectory, backed by recent product launches. In India, GST-related adjustments, given our unique three-tiered distribution model, had a one-time impact on primary sales; however secondary sales continue to outperform IPM, and we expect reported growth to normalize from Q3 onwards. Our specialty and innovation businesses progressed several important milestones this quarter including the global expansion of Ryaltris, the UK launch of Winlevi, the regulatory and clinical milestones achieved for QiNHAYOTM, and our IGI oncology assets. We remain committed to disciplined execution, advancing meaningful science, and delivering sustained value for our patients, partners, and all stakeholders.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets. The scrip advanced 1.12% to settle at Rs 1,897.50 on the BSE.Powered by Capital Market - Live

Net profit of Glenmark Pharmaceuticals rose 72.31% to Rs 610.35 crore in the quarter ended September 2025 as against Rs 354.21 crore during the previous quarter ended September 2024. Sales rose 76.56% to Rs 6003.79 crore in the quarter ended September 2025 as against Rs 3400.50 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales6003.793400.50 77 OPM %39.3017.70 - PBDT2493.72592.85 321 PBT2352.52472.57 398 NP610.35354.21 72 Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a third straight session in a row. The stock is quoting at Rs 1928.6, up 2.55% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.25% on the day, quoting at 25813.45. The Sensex is at 84244.6, down 0.28%. Glenmark Pharmaceuticals Ltd has risen around 1.82% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 3.31% in last one month and is currently quoting at 22686.8, up 0.44% on the day. The volume in the stock stood at 10.99 lakh shares today, compared to the daily average of 6.94 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1931.2, up 2.46% on the day. Glenmark Pharmaceuticals Ltd is up 29.81% in last one year as compared to a 10.06% spurt in NIFTY and a 5.77% spurt in the Nifty Pharma index.The PE of the stock is 28.26 based on TTM earnings ending June 25.Powered by Capital Market - Live

Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals, today announced that the National Medical Products Administration (NMPA) of China has approved RYALTRIS' Compound Nasal Spray (GSP 301 NS) for the treatment of Allergic Rhinitis (AR) in adults and children - specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adults and pediatric patients 12 years of age and older. The approval granted with zero supplementation requests is an important milestone in Glenmark's respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions.Powered by Capital Market - Live

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live

The product has been deemed bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (NDA - 019443). Glenmark plans to begin distribution in November 2025, further strengthening its injectables portfolio in the US market. According to IQVIA sales data for the 12-month period ending August 2025, the market for 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) achieved annual sales of approximately $63.8 million. Commenting on the launch, Marc Kikuchi, president & business head, North America said, 'We are pleased to announce the expansion of our injectable portfolio to include the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, which further reinforces our dedication to bring quality and affordable alternatives to market to patients in need.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets. The company's consolidated net profit tanked 23.4% to Rs 260.79 crore on 5.1% decline in revenue from operations to Rs 3059.33 crore in Q1 FY26 over Q1 FY25. Shares of Glenmark Pharmaceuticals fell 1.50% to Rs 1,869.60 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin distribution in November 2025. According to IQVIA' sales data for the 12-month period ending August 2025, the 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) market achieved annual sales of approximately $63.8 million. Powered by Capital Market - Live